ArticlePLoS neglected tropical diseases2019
Antimicrobial activity of Mycobacteriophage D29 Lysin B during Mycobacterium ulcerans infection.
Article in PLoS neglected tropical diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 33 citations in OpenAlex.
- Article
- Bacteriophage Lysins as Programmable Antimicrobials: Mechanisms, Engineering, and Translational Advances.Probiotics and antimicrobial proteins · 2026Review
- The peptidoglycan-binding domain regulates antimycobacterial activity of LysB by affecting its transportation and/or catalytic activity.Communications biology · 2026Article
- Exploring the molecular properties and bactericidal potential of Lysin B from mycobacteriophage WXIN.BMC microbiology · 2026Article
- Next-generation antimicrobials: A review of phage lysins as precision weapons against drug-resistant pathogens.Virulence · 2025Review
- Genome sequence of cluster B1Microbiology resource announcements · 2025Article
- Bacteriophage as a potential biotherapeutics to combat present-day crisis of multi-drug resistant pathogens.Heliyon · 2024Review
- Discovery and characterization of a novel LysinB from F2 sub-cluster mycobacteriophage RitSun.Scientific reports · 2024Article
- Targeting intracellular nontuberculous mycobacteria andMicrobiology spectrum · 2024Article
- The applications of animal models in phage therapy: An update.Human vaccines & immunotherapeutics · 2023Review
- Intrapulmonary Treatment with Mycobacteriophage LysB Rapidly Reduces Mycobacterium abscessus Burden.Antimicrobial agents and chemotherapy · 2023Article
- Identification of Toxic Proteins Encoded by Mycobacteriophage TM4 Using a Next-Generation Sequencing-Based Method.Microbiology spectrum · 2023Article
- Repurposing of statins for Buruli Ulcer treatment: antimicrobial activity againstFrontiers in microbiology · 2023Article
- Bacteriophages of Mycobacterium tuberculosis, their diversity, and potential therapeutic uses: a review.BMC infectious diseases · 2022Review
- A Review on Mycobacteriophages: From Classification to Applications.Pathogens (Basel, Switzerland) · 2022Review
- Exploration of Synergistic Action of Cell Wall-Degrading Enzymes against Mycobacterium tuberculosis.Antimicrobial agents and chemotherapy · 2021Article
- Engineered endolysin-based "artilysins" for controlling the gram-negative pathogen Helicobacter pylori.AMB Express · 2021Article
- Mycobacteriophages as Potential Therapeutic Agents against Drug-Resistant Tuberculosis.International journal of molecular sciences · 2021Review
- Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier.Pharmaceuticals (Basel, Switzerland) · 2021Review
- PLAN-M; Mycobacteriophage Endolysins Fused to Biodegradable Nanobeads Mitigate Mycobacterial Growth in Liquid and on Surfaces.Frontiers in microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Buruli Ulcer (BU) is a cutaneous disease caused by Mycobacterium ulcerans. The pathogenesis of this disease is closely related to the secretion of the toxin mycolactone that induces extensive destruction of the skin and soft tissues. Currently, there are no effective measures to prevent the disease and, despite availability of antibiotherapy and surgical treatments, these therapeutic options are often associated with severe side effects. Therefore, it is important to develop alternative strategies for the treatment of BU. Endolysins (lysins) are phage encoded enzymes that degrade peptidoglycan of bacterial cell walls. Over the past years, lysins have been emerging as alternative antimicrobial agents against bacterial infections. However, mycobacteria have an unusual outer membrane composed of mycolylarabinogalactan-peptidoglycan. To overcome this complex barrier, some mycobacteriophages encode a lipolytic enzyme, Lysin B (LysB). In this study, we demonstrate for the first time that recombinant LysB displays lytic activity against M. ulcerans isolates. Moreover, using a mouse model of M. ulcerans footpad infection, we show that subcutaneous treatment with LysB prevented further bacterial proliferation, associated with IFN-γ and TNF production in the draining lymph node. These findings highlight the potential use of lysins as a novel therapeutic approach against this neglected tropical disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.